Home
Gilead and MacroGenics Announce Oncology Collaboration to Develop Promising Bispecific Antibodies

Gilead and MacroGenics Announce Oncology Collaboration to Develop Promising Bispecific Antibodies

Today’s Highlights October 17, 2022

Gilead Sciences and MacroGenics Collaboration Announcement
Gilead Sciences (GILD) and MacroGenics (MGNX) announced an exclusive option and collaboration agreement to develop MGD024 using MacroGenics DART . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.
Today’s Highlights
,
October 17, 2022

Other Articles